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Abstract
Giant cell arteritis (GCA) is a vasculitis of medium and large sized vessels that occurs most often in people >50 years of age
with associated symptoms of fever, weight loss, headache and jaw claudication. Polymyalgia rheumatica (PMR), which is
characterized by aching and stiffness in the shoulders, hip girdle, neck and torso, is intimately associated with GCA, and ev-
idence suggests that GCA and PMR are two phases of the same disease. The occurrence of liver enzyme abnormalities in ei-
ther of these conditions is rare. Furthermore, as these conditions occur most commonly in the elderly population who may
be subject to polypharmacy, patients with elevated aminotransferases due to underlying GCA/PMR may mistakenly have
their abnormal liver function tests attributed to drug-induced liver injury. Given the potential complications of these dis-
eases if left untreated, including ischemic stroke and blindness, early recognition and treatment are critical. We report two
patients who developed severe cholestatic liver enzyme elevation, which had been initially attributed to drug toxicity, but
was ultimately caused by large vessel vasculitis, specifically GCA and PMR.
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Background
Cholestatic liver enzyme elevation occurs most commonly in the
setting of extrahepatic biliary obstruction or intrahepatic ductal
injury. Though rare, large vessel vasculitides may present with
abnormal liver function tests that primarily manifest as a rise in
serum alkaline phosphatase level with normal total bilirubin.
Histological changes of the liver in giant cell arteritis (GCA) and
polymyalgia rheumatic (PMR) are inconsistent and nonspecific
[1–4]. In most instances, hepatic enzymes normalize after ade-
quate treatment of the underlying vasculitis with corticosteroids.
There is currently a paucity of literature describing cholestatic
hepatitis secondary to large vessel vasculitides, and more
awareness of these diseases as an etiology for unexplained ele-
vation of liver enzymes is warranted, to assist in early diagnosis
and treatment of GCA/PMR.
Case 1
A 62-year-old male presented with a three-week history of fatigue,
fever and abnormal liver enzymes. The patient was diagnosed with
rheumatoid arthritis eight months prior to presentation, which
manifested with symptoms of decreased range of motion in his
hips and swollen proximal interphalangeal joints. He was initially
treated with prednisone and leflunomide but was transitioned
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to etanercept once weekly, with withdrawal of prednisone. After
the seventh dose of etanercept, the patient began experiencing fe-
vers up to 102F, general malaise, diaphoresis and a dull bilateral
headache. He denied any visual changes, temporal tenderness
or jaw claudication. The patient’s medications at that time also in-
cluded dexlansoprazole and atorvastatin. He had no significant
family history and was a social drinker. Physical examination was
significant for a mild increase in liver span. There was no abdomi-
nal tenderness, jaundice, temporal tenderness or joint swelling.
Laboratory tests revealed alkaline phosphatase of 1017 U/L, as-
partate transaminase (AST) of 306 U/L and alanine transaminase
(ALT) of 344 U/L. Complete blood cell count, coagulation panel
and basic metabolic panels were within normal limits, whereas
erythrocyte sedimentation rate (ESR) was 97 mm/h, and C-
reactive protein (CRP) was 16.3 mg/dL. Antinuclear antibody
(ANA), anti-smooth muscle antibody (ASMA), anti-mitochondrial
antibody (AMA), Cytomegalovirus polymerase chain reaction and
viral hepatitis A/B/C serologies were all negative. Abdominal ul-
trasound showed normal liver parenchyma, patent hepatic arter-
ies and veins and portal veins with normal direction of flow.
Computed tomography (CT) scan of the abdomen and pelvis was
unremarkable. There was no intrahepatic or extrahepatic ductal
dilatation. A liver core biopsy showed minimal nonspecific focal
portal and lobular inflammation.
Initially, the patient was thought to have drug-induced liver
injury secondary to etanercept. The patient was started on pred-
nisone 20 mg for treatment of drug-induced liver injury, which re-
sulted in improvement of his symptoms and normalization of his
liver enzymes. During a trial of a prednisone taper, however, the
patient’s AST, ALT, and alkaline phosphatase rose.
Magnetic resonance angiogram (MRA) of the abdomen and
pelvis and magnetic resonance cholangiogram (MRCP) demon-
strated an abnormal aortic wall with edema and enhancement
consistent with vasculitis as well as abnormal intrahepatic ducts
with areas of stenosis suggestive of cholangitis (Figures 1 and 2).
In correlating the radiologic findings with his physical symptoms
of fatigue, fever, joint pain and elevated ESR, the patient was di-
agnosed with giant cell arteritis. Prednisone 60 mg was started,
and his liver enzymes normalized again two weeks later and re-
mained within normal limits (Table 1). Follow-up MRCP, after
liver enzymes normalized, revealed no evidence of ductal
abnormality.
Case 2
A 74-year-old male presented to the emergency room with a
two-to-three week history of increasing lethargy, intermittent
fever and anorexia. Prior to his visit to the emergency room, he
was seen by his general practitioner; due to muscle pain, he was
treated for one week with celecoxib without any significant im-
provement of his symptoms. The patient did not have any ab-
dominal complaints. The patient had a history of hypertension
and hyperlipidemia and was treated for several years with los-
artan and simvastatin. He did not have any history of liver dis-
ease and had very modest alcohol consumption. Labs were
significant for AST 222 U/L, ALT 190 U/L, alkaline phosphatase
411 U/L, gamma-glutamyl transpeptidase (GGT) 231 U/L, normal
bilirubin, serum albumin 2.6 g/dL and normal international nor-
malized ratio. The patient had a hemoglobin of 10.2 g/dL, plate-
let count of 600 103/mL and ESR of 100 mm/h. Serologies for
hepatitis A, B, C, E, Cytomegalovirus, and Epstein-Barr virus as
well as AMA, ANA and ASMA were negative. He was hospital-
ized for three days for work-up of a possible malignancy since
this was considered the most likely diagnosis. CT scan of the ab-
domen was however normal.
The initial diagnosis was drug-induced liver injury, and both
simvastatin and losartan were discontinued. The patient’s liver
tests remained elevated one week later at a follow-up appoint-
ment at the outpatient clinic. Detailed history-taking elicited
additional symptoms of muscle pain, mostly in the thighs and
shoulders as well as difficulty standing up from a chair and lift-
ing his arms. History of these characteristic symptoms of PMR
had not been obtained during the initial hospitalization. On
exam, the patient’s proximal muscles were very tender,
although he was not tender over the temporal arteries and did
not have visual symptoms.
Due to his symptoms and laboratory parameters, he was clin-
ically diagnosed with PMR. He was started on prednisolone 40 mg
for one week with near-complete resolution of his myalgia. One
Figure 1. MRCP demonstrates significant irregularity of the intrahepatic bile
ducts with areas of narrowing and beading-type appearance suggestive of
cholangitis.
Figure 2. The aortic wall is diffusely thickened. There is marked edema as noted
on T2 STIR sequences as well as increase in signal on high B-value consistent
with edema. On post-contrast administration, there is interval increase in the
enhancement of the aortic wall suggestive of active vasculitis.
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week later, his alkaline phosphatase decreased from 411 U/L to
169 U/L, and ESR decreased from 100 to 30 mm/h. After four
weeks of treatment with prednisolone 40 mg/d for 2 weeks and
20 mg/d for 2 weeks, his liver enzymes, platelets and albumin
were normal. His ESR was also normal at 10 mm/h.
Discussion
We present two patients with severe elevation of alkaline phos-
phatase secondary to GCA/PMR. Although elevation of hepatic
aminotransferases has been described in those with GCA/PMR
[5], this association has been depicted only in a small number of
case reports [3,6–11]. In most instances, patients present with
constitutional symptoms of fever, weight loss, night sweats and
anorexia with elevations in ESR and CRP. When liver tests are
abnormal, a rise in serum alkaline phosphatase is consistently
seen [12], while hyperbilirubinemia is not typically seen, and se-
rum AST and ALT levels may be normal or elevated [7].
Histological changes of the liver in GCA/PMR are inconsis-
tent and nonspecific. These may include normal histology [1],
moderate bile stasis [2], fatty degeneration [3] and nonspecific
portal tract inflammatory infiltration [4]. Although the underly-
ing pathophysiology remains to be elucidated, it is proposed
that the abnormal liver enzymes result from inflammation of
the hepatic artery [13]. In one report, biopsy of the hepatic and
temporal arteries in the same patient demonstrated lympho-
cytic inflammatory infiltrates and numerous giant cells, which
are typical of giant cell arteritis [9]. The elevated alkaline phos-
phatase often associated with GCA/PMR is likely a result of in-
jury to bile duct epithelial cells due to adjacent arteritis.
In the first case we presented, MRA showed increased arterial
wall enhancement and a thickened aortic wall. There was also ir-
regularity of the intrahepatic bile ducts with a beading-type ap-
pearance consistent with cholangitis secondary to arteritis of
hepatic vasculature. Similarly, in a case reported by Prabhavalkar
et al, a 60-year-old female was found to have elevated ESR, alka-
line phosphatase and AST [6]. A whole body positron emission
tomography scan demonstrated increased metabolic activity
within the central large vessels, thoracic and abdominal aorta,
and proximal carotids and subclavian arteries consistent with a
large vessel vasculitis. A temporal artery biopsy confirmed the di-
agnosis of GCA. The severity of the clinical manifestations and
abnormal liver function tests appear to correspond to the
severity of the arteritis. In most cases, including the two pre-
sented above, there is complete resolution of abnormal liver en-
zymes after adequate corticosteroid treatment [7].
In patients with cholestatic liver enzymes secondary to
large vessel vasculitis such as GCA/PMR, we recommend im-
mediate referral to a rheumatologist to determine proper
dosing of corticosteroid-based therapy [14]. As the abnormal
liver enzymes correlate with disease activity, it is expected
that control of the underlying vasculitis will lead to improve-
ment in aminotransferase levels. The patient should be
closely followed by a rheumatologist to adjust corticosteroid
dosing, with the goal of achieving disease remission. Liver bi-
opsy is not necessary if the patient responds appropriately to
treatment.
Given the seriousness of untreated GCA/PMR with potential
complications of blindness or ischemic cerebrovascular acci-
dent, it is crucial to recognize the possibility of this condition as
a cause of liver enzyme elevation. Therefore, in patients aged
>50 years with elevated liver enzymes, persistent fever and ele-
vated ESR, consideration should be given to diagnosis and treat-
ment of large vessel vasculitis.
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